Amount of qualified sufferers: CDEC reviewed the uncertainty in the quantity of clients with moderately extreme to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some sufferers who're classified as possessing mild or reasonable illness may have a extreme bleeding